{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:36:09Z","timestamp":1789832169891,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ygyno.2012.06.034","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T18:14:05Z","timestamp":1341252845000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone"],"prefix":"10.1016","volume":"127","clinical-trial-number":[{"clinical-trial-number":"nct00113607","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Carolyn N.","family":"Krasner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Lardelli","family":"Claret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn Choi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.06.034_bb0005","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/gyno.1994.1082","article-title":"Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment","volume":"53","author":"Del Campo","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.","volume":"78","author":"Aabo","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2012.06.034_bb0035","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0040","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0045","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0055","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00001813-199811000-00006","article-title":"Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost","volume":"9","author":"Patnaik","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2004.01.017","article-title":"A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians","volume":"93","author":"Calhoun","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0070","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/cncr.24520","article-title":"Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials","volume":"115","author":"von Gruenigen","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0080","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2006.01.059","article-title":"Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy","volume":"103","author":"von Gruenigen","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0090","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1200\/JCO.2005.08.147","article-title":"Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study","volume":"23","author":"Wenzel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0100","first-page":"169","article-title":"Quality of life in patients with ovarian cancer: current state of research","volume":"4","author":"Montazeri","year":"1996","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0110","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0115","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0277-9536(94)90005-1","article-title":"Test-retest reliability of health state valuations collected with the EuroQol questionnaire","volume":"39","author":"van Agt","year":"1994","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","volume":"37","author":"Cull","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MLR.0b013e3182064aa2","article-title":"Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials","volume":"49","author":"Dinan","year":"2011","journal-title":"Med Care"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0130","series-title":"Design and analysis of quality of life studies in clinical trials","author":"Fairclough","year":"2010"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0135","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11864-007-0049-6","article-title":"Quality-of-life issues in the management of epithelial ovarian cancer","volume":"8","author":"Lowe","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdq353","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval","volume":"22","author":"Kaye","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.034_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2010","journal-title":"Ann Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812004854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812004854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:31:54Z","timestamp":1758771114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812004854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0090825812004854"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.034","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954097.793459883","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}